Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly traded company in health care to hit the milestone.

Lilly’s stock has surged in large part because of the company’s success in seizing the biggest potential market in the history of the drug industry: the class of weight loss medicines known as GLP-1s.

The company’s injection, sold as Zepbound and Mounjaro, is on track to be the top-selling drug in the world this year.

Only a handful of publicly traded companies, mostly in technology, have reached the $1 trillion benchmark. Nvidia, the AI chipmaker, recently became the first publicly traded company worth $5 trillion. The second-most valuable health care company, Johnson &Johnson, is worth about $500 billion.

Under the

See Full Page